#1 Clinical Trials Search in Europe

Gsk4532990A

GSK4532990A is being studied in clinical trials for its potential to treat liver diseases, specifically nonalcoholic steatohepatitis (NASH) and alcohol-related liver disease (ALD). These trials aim to assess the drug’s safety, effectiveness, and optimal dosing in patients with various stages of liver fibrosis and impairment. The studies focus on important markers of liver health and disease progression, offering hope for patients with these challenging conditions.

Table of Contents

What is GSK4532990A?

GSK4532990A, also known as ADS-006 sodium, is an investigational drug being developed by GlaxoSmithKline for the treatment of alcohol-related liver disease (ALD)[1]. It is a new type of medication called a GalNAc conjugated siRNA therapy, which means it uses a special technology to target and modify specific genes in the liver[1].

Target Condition: Alcohol-Related Liver Disease

Alcohol-related liver disease (ALD) is a serious condition caused by excessive alcohol consumption. It can lead to inflammation, fat accumulation, and scarring (fibrosis) in the liver. In severe cases, it can progress to cirrhosis, liver failure, or liver cancer[1]. GSK4532990A is being studied as a potential treatment for people with ALD, including those with more advanced stages of liver damage.

How GSK4532990A Works

While the exact mechanism is not fully described in the provided information, GSK4532990A is designed to target specific genes in the liver that may be involved in the progression of ALD. By modifying these genes, the drug aims to reduce inflammation, decrease fat accumulation, and potentially reverse some of the liver damage caused by alcohol[1].

Clinical Trials

GSK4532990A is currently being studied in clinical trials to evaluate its safety and effectiveness. Two main studies are underway:

  1. A Phase 2b study called HORIZON, which is investigating the drug’s effects on people with non-alcoholic steatohepatitis (NASH), a similar liver condition[2].
  2. A Phase 2 study called STARLIGHT, which is specifically focused on patients with alcohol-related liver disease[1].

These trials aim to determine if GSK4532990A can improve liver health, reduce scarring, and potentially reverse some of the damage caused by alcohol.

Potential Benefits

If successful, GSK4532990A could offer several potential benefits for people with ALD:

  • Reduction in liver inflammation and fat accumulation
  • Improvement in liver function tests
  • Decrease in liver stiffness, which is a sign of fibrosis
  • Potential reversal of liver scarring
  • Improved overall liver health and function

Administration and Dosing

GSK4532990A is administered as a subcutaneous injection, which means it is injected under the skin[1]. The clinical trials are testing different dosing regimens, including:

  • 25 mg once every 4 weeks
  • 100 mg once every 4 weeks
  • 400 mg once every 4 weeks
  • A loading dose of 400 mg followed by 400 mg every 12 weeks

The optimal dosing schedule will be determined based on the results of these studies.

Who May Be Eligible for Treatment?

The clinical trials for GSK4532990A have specific eligibility criteria. Generally, participants must:

  • Be adults aged 18-65 years old
  • Have a history of excessive alcohol consumption
  • Show signs of liver damage related to alcohol use
  • Meet certain liver function test criteria
  • Not have other serious liver conditions or diseases

It’s important to note that eligibility for the clinical trials does not necessarily reflect who might be eligible for the treatment if it becomes approved in the future[1].

Safety Considerations

As with any investigational drug, the safety of GSK4532990A is being closely monitored in clinical trials. Some potential safety considerations include:

  • Injection site reactions
  • Potential effects on liver function
  • Interactions with other medications
  • Long-term safety profile

The ongoing clinical trials will help determine the overall safety profile of GSK4532990A and identify any potential side effects or risks[1].

In conclusion, GSK4532990A represents a promising new approach to treating alcohol-related liver disease. While still in the investigational stage, this drug offers hope for people suffering from this serious condition. As research continues, we’ll learn more about its effectiveness and safety profile.

Aspect Details
Drug Name GSK4532990A
Conditions Studied Nonalcoholic Steatohepatitis (NASH), Alcohol-related Liver Disease (ALD)
Administration Method Subcutaneous injection
Dosing Schedules Various, including 25mg, 100mg, 400mg every 4 weeks; 400mg every 12 weeks
Primary Outcomes Changes in liver stiffness, MELD scores, NASH resolution, fibrosis improvement
Key Eligibility Criteria Adults 18-75, confirmed NASH or ALD, specific levels of liver fibrosis
Safety Assessments Adverse events, lab tests, ECG changes, vital signs
Study Phases Phase 2b for NASH, Phase 2 for ALD

FAQ

  • What is GSK4532990A and how does it work? GSK4532990A is an investigational drug that targets specific enzymes involved in liver fat metabolism. It's designed to potentially reduce liver fat, inflammation, and fibrosis in patients with liver diseases like NASH and ALD.
  • Who is eligible to participate in these clinical trials? Eligibility varies by study, but generally includes adults aged 18-75 with confirmed NASH or ALD, specific levels of liver fibrosis, and other health criteria. Some trials exclude patients with severe liver impairment or other significant health issues.
  • How is the drug administered in these trials? GSK4532990A is given as a subcutaneous injection (under the skin). The dosing schedule varies by trial, with some studies testing different doses given every 4 weeks or every 12 weeks.
  • What are the main outcomes being measured in these trials? The trials are primarily looking at changes in liver stiffness (measured by FibroScan), MELD scores (a measure of liver disease severity), and resolution of NASH or improvement in fibrosis. They also assess safety and how the body processes the drug.
  • How long do these clinical trials last? The duration varies, but many of the assessments focus on changes at 28 weeks (about 6 months) of treatment. Some trials may have longer follow-up periods to assess long-term effects and safety.

Ongoing Clinical Trials on Gsk4532990A

  • Study on GSK4532990 for Adults with Nonalcoholic Steatohepatitis (NASH)

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Greece Italy Spain

Glossary

  • NASH: Nonalcoholic Steatohepatitis: A type of fatty liver disease not caused by alcohol, characterized by inflammation and liver cell damage.
  • ALD: Alcohol-related Liver Disease: Liver damage caused by excessive alcohol consumption, which can lead to fatty liver, inflammation, and scarring.
  • Fibrosis: The formation of scar tissue in the liver, which can occur due to long-term liver damage from various causes.
  • MELD score: Model for End-Stage Liver Disease score: A numerical scale used to assess the severity of chronic liver disease and predict survival.
  • FibroScan: A non-invasive test that measures liver stiffness to assess the degree of liver fibrosis or scarring.
  • LSM: Liver Stiffness Measurement: A measure of liver fibrosis obtained through techniques like FibroScan.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of tissue just beneath the skin.
  • Cirrhosis: Advanced scarring of the liver, often a result of long-term liver damage from various causes including NASH and ALD.
  • Hepatic impairment: Reduced liver function, which can occur due to various liver diseases and affects how the body processes medications and toxins.
  • Steatosis: Accumulation of fat in liver cells, an early stage of fatty liver disease that can progress to more severe forms like NASH.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-gsk4532990-for-adults-aged-18-65-with-alcohol-related-liver-disease/
  2. http://clinicaltrials.eu/trial/study-on-gsk4532990-for-adults-with-nonalcoholic-steatohepatitis-nash/